HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...

NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics.

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in almost three weeks, drawing heavy ...

NRx Pharmaceuticals (NRXP) announced that it has entered into a binding agreement for a registered direct offering of its common stock with ...

NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101.

Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd.

NRx Pharmaceuticals, Inc. appointed Mike Taylor as a Class I member of its Board of Directors. Taylor, aged 50, brings with him 25 years of experience in the global credit business, specializing in ...

HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP) ...

Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced engagement of BTIG, a leading global financial services ...

The Company has recently announced execution of an agreement for $27 million in funding for HOPE <a target=_blank href= ...